Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzGene, use the "Keyword" search on the
AlzGene search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzGene - Gene overview of all published AD-association studies for A2M
Gene:
A2M
(CPAMD5; FWP007; S863-7; alpha 2M)
View on MSGene
View on PDGene
Protein:
alpha-2-macroglobulin
Chromosome:
12
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 13 September 2010
1. Case-Control Studies (by ethnic group)
AD Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Alvarez, 1999
Spain
CL
1
(detail)
190
(-)
C
-
72 + 9.1
(-)
400
(-)
-
Positive
Bagli, 2000
Germany
CL
1
(detail)
102
(67%)
C
-
74.4 + 10.3
(51-101)
191
(52%)
70.6 + 11.4
(50-100)
Negative
Blennow, 2000
Europe (I)
CL
1
(detail)
449
(62%)
C
-
73.1 + 10.4
(-)
349
(44%)
66.7 + 12.5
(-)
Negative
Blennow, 2000
Europe (II)
CL
1
(detail)
94
(62%)
N
-
80.1 + 8.2
(-)
107
(47%)
76.6 + 9.4
(-)
Negative
Blomqvist, 2005
Overlaps with
Emahazion, 2001
CL
1
(detail)
-
-
-
-
-
-
n.a.
Blomqvist, 2005
Overlaps with
Prince, 2001
CL
1
(detail)
-
-
-
-
-
-
n.a.
Bruno, 2010
Italy
CL
1
(detail)
125
(55%)
C
-
75.4 + 7
(-)
310
(56%)
74.7 + 6.6
(-)
Positive
Bullido, 2000
Spain
CL
1
(detail)
154
(60%)
C
70.4 + 6.3
(-)
-
217
(62%)
72 + 7.6
(-)
Negative
Clarimon, 2003
Spain
CL
2
(detail)
112
(73%)
C
-
76.7 + 5.4
(-)
89
(52%)
74.8 + 5.2
(-)
Negative
Colacicco, 2007
Italy
CL
1
(detail)
169
(63%)
C
69.5 + 9.7
(-)
69.4 + 5.2
(-)
264
(55%)
71.7 + 7
(-)
Negative
Corder, 2008
Overlaps with
Prince, 2001
CL
1
(detail)
938
(-)
U
-
-
397
(-)
-
n.a.
Depboylu, 2006
Germany
CL
1
(detail)
271
(37%)
C
-
70.7 + 9.6
(50-95)
280
(31%)
66.9 + 10.6
(50-93)
Positive
Dodel, 2000
USA & Europe
CL
1
(detail)
309
(-)
C
-
72.7 + 9.5
(50-94)
281
(-)
72.9 + 9.4
(51-94)
Positive
Dow, 1999
UK
CL
1
(detail)
230
(-)
M
-
-
218
(-)
-
Negative
Edwards, 2009
USA
CL
1
(detail)
296
(-)
M
71.7 + 7.8
(-)
79 + 6.6
(-)
566
(-)
73.6 + 6.3
(-)
Negative
Emahazion, 2001
Scotland
CL
1
(detail)
121
(-)
C
-
-
152
(-)
-
Negative
Gibson, 2000
UK
CL
2
(detail)
195
(66%)
N
-
79.8
(57-98)
107
(58%)
79
(60-100)
Trend
Halimi, 2000
France
CL
1
(detail)
281
(-)
C
-
76.9 + 8.3
(-)
84
(-)
77 + 7.4
(-)
Negative
Higuchi, 2000
Unknown
2
(detail)
85
(56%)
N
-
77.6 + 7.3
(-)
65
(46%)
60.9 + 14.8
(-)
Negative
Janka, 2002
Hungary
1
(detail)
53
(68%)
C
69 + 4.2
(-)
73 + 6.2
(-)
51
(73%)
72 + 7
(-)
Negative
Korovaitseva, 1999
Russia
CL
1
(detail)
146
(-)
C
-
-
160
(-)
-
Negative
Koster, 2000
Netherlands
PO
2
(detail)
456
(71%)
C
76.5 + 6.6
(-)
-
358
(58%)
74.5 + 4.4
(-)
Negative
Kovacs, 1999
UK
CL
1
(detail)
96
(65%)
N
-
78.6 + 9.8
(-)
64
(42%)
70.6 + 10.3
(-)
Negative
Mariani, 2006
Italy
CL
1
(detail)
100
(74%)
C
-
76.1 + 7.1
(-)
136
(74%)
72.9 + 7.3
(-)
Negative
McIlroy, 2001
Ireland
CL
2
(detail)
219
(67%)
C
75.1
(-)
77.5 + 6
(-)
237
(70%)
77.2 + 6.1
(-)
Negative
Myllykangas, 1999
Finland
PO
2
(detail)
114
(82%)
M
87.2 + 4.4
(-)
89.1 + 2.7
(-)
204
(80%)
88.1 + 2.7
(-)
Positive
Nacmias, 2001
Italy
CL
2
(detail)
179
(-)
M
66.7 + 6.3
(-)
-
98
(-)
74.5 + 25.1
(19-106)
Negative
Nicosia, 2001
Italy
CL
1
(detail)
100
(75%)
C
-
79.2 + 7.3
(-)
49
(63%)
68.3 + 9.2
(-)
Negative
Poduslo, 2002
USA
CL
2
(detail)
398
(67%)
M
69.4 + 8.5
(44-92)
-
216
(-)
-
Negative
Prince, 2001
Sweden
CL
1
(detail)
204
(61%)
M
-
-
186
(58%)
-
Negative
Rogaeva, 1999
USA
CL
1
(detail)
185
(-)
C
-
-
156
(-)
-
Negative
Rogaeva, 1999
Canada
CL
1
(detail)
207
(-)
C
-
-
164
(-)
-
Negative
Rudrasingham, 1999
UK
CL
1
(detail)
152
(63%)
U
71.9 + 8.1
(-)
-
99
(55%)
72.6 + 6.6
(-)
Negative
Rudrasingham, 1999
France
CL
1
(detail)
616
(63%)
U
69.4 + 8.6
(-)
-
648
(63%)
73.1 + 8.5
(-)
Negative
Scacchi, 2002
Italy
CL
1
(detail)
93
(76%)
C
-
85.8 + 3.8
(80-95)
157
(59%)
83.9 + 3.1
(80-99)
Negative
Singleton, 1999
UK
CL
2
(detail)
213
(64%)
N
-
79.2 + 0.6
(57-98)
116
(54%)
78.9 + 10.8
(57-100)
Trend
Sleegers, 2004
Netherlands
PO
1
(detail)
161
(78%)
C
73.4 + 5.3
(-)
76.9 + 5.3
(-)
120
(-)
-
Negative
Styczynska, 2003
Poland
CL
1
(detail)
100
(66%)
C
71 + 4.6
(-)
76.4 + 4.7
(-)
100
(58%)
74.2 + 6.6
(-)
Negative
Wang, 2001
USA
CL
2
(detail)
555
(68%)
M
71.3 + 6.1
(-)
77.4 + 6.7
(-)
446
(68%)
75.7 + 4.9
(-)
Negative
Wavrant-DeVrieze, 1999
UK
CL
1
(detail)
119
(-)
U
-
-
114
(-)
-
Negative
Wavrant-DeVrieze, 1999
USA (I)
CL
1
(detail)
329
(-)
U
-
-
487
(-)
-
Negative
Wavrant-DeVrieze, 1999
USA (II)
CL
1
(detail)
136
(-)
U
-
-
145
(-)
-
Negative
Wavrant-DeVrieze, 1999
France
CL
1
(detail)
616
(-)
U
-
-
648
(-)
-
Negative
Wehr, 2006
Poland
CL
1
(detail)
100
(66%)
C
-
71.8 + 7.9
(52-91)
144
(53%)
70.5 + 8.8
(47-93)
Negative
Zappia, 2002
Italy
CL
1
(detail)
132
(60%)
C
-
72.3 + 6.4
(-)
184
(55%)
76.6 + 7.5
(-)
Positive
Zappia, 2004
Italy
CL
1
(detail)
148
(61%)
C
-
71.3 + 7.4
(-)
158
(54%)
74.1 + 6.7
(-)
Positive
Zill, 2000
Germany
CL
2
(detail)
88
(57%)
C
-
73 + 9
(-)
118
(53%)
47 + 12
(-)
Negative
Asian
Bian, 2005
China
CL
6
(detail)
216
(-)
C
74.7
(-)
-
200
(-)
-
Negative
Cai, 2005
China
1
(detail)
116
(62%)
U
-
74.5
(39-91)
271
(56%)
57.8
(33-95)
Negative
Chen, 1999
China
CL
1
(detail)
196
(74%)
M
-
79.5 + 8.5
(-)
180
(66%)
79.2 + 7.5
(-)
Negative
Chen, 2004
China
CL,PO
2
(detail)
158
(53%)
C
69.4 + 9.4
(-)
-
195
(45%)
70 + 7.8
(-)
Trend
Higuchi, 2000
Japan
CL
2
(detail)
426
(73%)
C
-
76.2 + 9
(-)
382
(69%)
74 + 5.6
(-)
Negative
Hu, 1999
Same as Hu, 2000
CL
1
(detail)
-
-
-
-
-
-
n.a.
Hu, 2000
Taiwan
CL
2
(detail)
82
(-)
C
-
78.2
(62-96)
110
(-)
79.2
(67-87)
Negative
Jhoo, 2001
Korea
CL
1
(detail)
100
(77%)
C
68.1 + 8.2
(-)
71.2 + 7.8
(55-85)
203
(78%)
69 + 4.7
(54-83)
Positive
Ki, 2001
Korea
CL
1
(detail)
89
(78%)
C
73.1 + 5.8
(-)
-
50
(58%)
73.2 + 7.8
(-)
Negative
Shibata, 1999
Japan
CL
1
(detail)
56
(41%)
C
69.2 + 10.2
(-)
72.2 + 9.5
(-)
69
(42%)
71 + 8.1
(-)
Negative
Shibata, 2000
Japan
CL
1
(detail)
111
(-)
M
-
69.6 + 10.4
(-)
95
(-)
69.8 + 9.3
(-)
Negative
Sodeyama, 2000
Japan
CL
1
(detail)
62
(-)
N
-
85.8 + 7.8
(62-104)
90
(-)
85.2 + 7.8
(66-101)
Negative
Song, 2010
China
CL
2
(detail)
179
(60%)
C
68.2 + 6.5
(-)
-
179
(60%)
67.2 + 6.5
(-)
Positive
Tang, 2002
China
CL
1
(detail)
114
(61%)
C
69.4 + 7.8
(-)
74.6 + 7.5
(39-91)
190
(55%)
55.8 + 15.5
(33-95)
Positive
Yamada, 1999
Overlaps with
Yamada, 2002
CL
1
(detail)
-
-
-
-
-
-
n.a.
Yamada, 2002
Japan
CL
1
(detail)
82
(-)
N
-
86.1 + 7.9
(62-104)
119
(-)
85.7 + 8
(65-103)
Negative
Hispanic
Camelo, 2004
Colombia
CL
1
(detail)
83
(72%)
C
-
69 + 8.9
(-)
69
(72%)
71.4 + 12.3
(-)
Negative
Other/Mixed
Crawford, 1999
USA
CL
1
(detail)
295
(56%)
C
73.1 + 6.4
(-)
-
113
(62%)
72.7 + 7.7
(-)
Negative
Crawford, 1999
USA
CL
1
(detail)
103
(-)
C
-
-
83
(-)
-
Negative
Liao, 1998
USA & Europe
CL
1
(detail)
737
(-)
M
-
-
449
(-)
-
Positive
Perry, 2001
USA
CL
1
(detail)
111
(78%)
M
70.8 + 7.8
(-)
71.3 + 7.7
(-)
78
(76%)
75.2 + 7.6
(-)
Negative
Rudrasingham, 1999
USA (I)
CL
1
(detail)
143
(62%)
U
73.7 + 9.5
(-)
-
144
(65%)
77 + 9.2
(-)
Negative
Rudrasingham, 1999
USA (II)
CL
1
(detail)
327
(65%)
U
75.5 + 9.7
(-)
-
487
(67%)
82.7 + 7.5
(-)
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Blacker, 1998
USA (NIMH)
1
(detail)
104
217
(-)
M
-
-
181
(-)
-
Positive
Edwards, 2009
Overlaps with
Rogaeva, 1999
2
(detail)
738
-
M
72.3 + 9.1
(-)
74.8 + 11
(-)
-
-
Positive
Poduslo, 2002
USA
2
(detail)
89
181
(-)
M
-
-
146
(-)
-
Trend
Poduslo, 2002
USA (NIMH)
2
(detail)
17
51
(63%)
M
68.5 + 4.9
(59-81)
-
20
(60%)
77.4 + 6
(66-87)
Positive
Rogaeva, 1999
USA (DUKE)
0
60
-
C
-
-
-
-
Negative
Rogaeva, 1999
Canada
0
45
-
C
-
-
-
-
Negative
Saunders, 2003
USA (NIMH)
2
(detail)
437
-
M
-
-
-
-
Positive
Hispanic
Romas, 2000
USA, Caribbean
2
(detail)
51
100
(-)
C
74.4 + 9.5
(42-90)
-
47
(-)
-
Positive
Other/Mixed
Rogaeva, 1999
USA (NIMH)
1
(detail)
143
-
M
-
-
-
-
Trend
Rudrasingham, 1999
USA (NIMH)
1
(detail)
270
-
U
-
-
-
-
Positive
Rudrasingham, 1999
USA (NIA)
1
(detail)
125
-
U
-
-
-
-
Trend
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-)
: Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
APOE
PICALM
MS4A6A
MS4A4A
MS4A4E
EPHA1
CR1
CLU
CD33
CD2AP
BIN1
ABCA7
ARID5B
CELF2
APOC4
BCAM
CLPTM1
PVRL2
LOC3884...
TNK1
MYH13
TOMM40
PCK1
SORL1
LMNA
PGBD1
UBD
GWA_7p1...
GAB2
GOLM1
GWA_15q...
GWA_9p2...
MTHFD1L
LRAT
FAM113B
PCDH11X
GWA_14q...
ATXN1
ADAM10
CD36
DPYS
TGM4
HMMR
LAMB1
PPP3CB
ADORA2B
MTP18
ESR1
CYP19A1
LIPA
CH25H
IL1RN
LPA
MTR
FAS
CHAT
CHRNA2
CHRNA6
CHRNA7
HTR2A
PIN1
NTRK2
SERPINA...
DLST
MAPT/ST...
APOC1
LRRTM3
REN
TNFRSF1...
PIK3R1
FYN
PPP1R3A
NDUFA8
MAPK8IP...
GRIN2B
TNFRSF1...
NDUFA6
PTGS2
HFE
ABCA1
LRP8
PPARG
APBB2
LDLR
IL10
BDNF
PPARA
SOAT1
NOS3
CHRNB2
CETP
MARCH5
ACE
PON1
PON2
CDK5
CTSD
VR22
LRP1
IL6
BACE1
BACE2
PSEN2
PLAU
GSTO1
GSTO2
PRSS11
IDE
CST3
PRNP
NCSTN
TF
MME
PSEN1
TCF7L2
DYRK1A
SORCS2
SORCS3
F11R
TUBB
GRN
NEDD9
ARMS2
SMAD3
VCP
WWC1
DNM2
EBF3
EIF2AK2
SEC24C
SGPL1
ABCG1
LSS
ABCG4
CYP39A1
NCAPD2
GAPDHS
ACTA2
KCNMA1
MYST4
SCD
ANK3
GOT1
SORCS1
TAP2
ENTPD7
DNMBP
CXCL10
VPS26A
C12orf4...
CCNT1
DAPK1
POMT1
IREB2
HMGCR
IGF1R
ABCB1
DSC1
NQO1
HMOX1
LIPC
HMGCS1
RFTN1
APOA1BP
FDPS
HMGCS2
PRKAB2
ADAM12
DHCR24
SOS2
ABCC9
GRB14
HK1
IRS1
NEUROD1
PDE3B
PPARGC1...
PPP1CC
SLC2A2
HECTD2
PITRM1
TARDBP
CDKN2A
IGF1
CSK
CBLC
CARD8
HMOX2
TRPC4AP
GSTZ1
NUMB
POMT2
TMEM63C
THRA
TACR2
OLIG2
TTR
TNMD
EFNA5
MAGI2
CAND1
PPIL2
CDKN2BA...
PTPLA
ACAT2
CHRNB4
DGKB
GWA_10q...
GWA_18q...
GWA_3q2...
HPCAL1
EXOC3L2
GWA_3p2...
ZNF292
PATHWAY...
PATHWAY...
PATHWAY...
TP63
TMEM132...
RGS6
NXPH1
NCAM2
GLOD4
EPHA4
EPC2
CCDC134
ATP6V0A...
ARL5B
AGPAT1
AlzGene Top Results
Top Results Details
1.
APOE_e2/3/4
2.
BIN1
3.
CLU
4.
ABCA7
5.
CR1
6.
PICALM
7.
MS4A6A
8.
CD33
9.
MS4A4E
10.
CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Proud supporter of the AlzGene database.
The PDGene database
is supported by a grant from
The Michael J. Fox Foundation
in partnership with the
Alzheimer Research Forum
.
NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.